Beta-amyloid PET/CT to See If AL-CA Therapy Works

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this Phase 2, single-center study, researchers use beta-amyloid PET/CT imaging to look for changes in amyloid burden after one year of therapy for AL-CA. They collect demographics, clinical data, and PET imaging to characterize any treatment-related changes from baseline. The goal is to determine if these molecular imaging markers reflect therapeutic response beyond standard biomarkers and imaging. Outcomes focus on whether amyloid burden reduction corresponds to clinical improvements.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 y；
2. were proven newly diagnosed AL-CA by standard criteria;
3. subsequently received first-line therapies including anti-plasma cell therapy or targeted therapy;
4. must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.

Exclusion Criteria:

1. received therapy with an approved treatment (e.g., Bortezomib, Daratumumab) prior to enrollment;
2. pregnancy or breastfeeding;
3. severe claustrophobia;
4. any condition deemed by the investigator to interfere with study results or increase participant risk.

Where it's running

• Peking Union Medical College Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Li Huo
• Email: huoli@pumch.cn
• Phone: +86 18612672038

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TQB2934 injection for systemic light chain amyloidosis

  This trial will test whether a subcutaneous injection of TQB2934 is safe and can improve blood response in adults with relapsed or refractory systemic light chain amyloidosis who have had daratumumab and bortezomib.

  Recruiting Phase 1/2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 26 other locations · NCT07266116

• Low-dose BCMA/CD3 (CM336) treatment for newly diagnosed AL (light-chain) amyloidosis

  This trial will try a low-dose BCMA/CD3 bispecific antibody (CM336) in adults newly diagnosed with systemic light-chain (AL) amyloidosis to see if it is safe and lowers abnormal light-chain levels and helps organ function.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07151690

• How well minimal residual disease is cleared in AL amyloidosis after first-line Dara-BorCyD

  This study tests whether achieving very good partial or complete marrow responses with Dara-BorCyD and planned stem cell transplant helps AL amyloidosis patients, by looking at minimal residual disease after treatment.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07215494

• Using daratumumab to treat patients with light chain amyloidosis

  This study is testing how well daratumumab works for treating light chain amyloidosis in different groups of patients to find the best way to help them.

  Recruiting Nanjing University School of Medicine · Nanjing, Jiangsu · NCT06376214

• Dual-target CAR T therapy (CD19 and BCMA) for relapsed or refractory AL (light-chain) amyloidosis

  This trial will try AZD0120, a CAR T cell therapy that targets CD19 and BCMA, to see if it is safe and helps people with relapsed or refractory AL (light-chain) amyloidosis.

  Recruiting at 15 sites Phase 1/2 Alexion Pharmaceuticals, Inc. · Phoenix, Arizona and 17 other locations · NCT07081646

• HBI0101 CAR-T therapy for multiple myeloma and light-chain amyloidosis

  This study is testing a new CAR-T therapy called HBI0101 to see if it can help people with relapsed or hard-to-treat multiple myeloma and light-chain amyloidosis feel better.

  Recruiting Phase 2 Hadassah Medical Organization · Jerusalem · NCT06971380

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.